Select your location

We have detected that you are here: Switzerland.
You will be redirected to the website for: SCHILLER Sales Switzerland
in: English.
Would you like to see the content for another country or in another language?

Select country
Continue

HyperQ Stress

Non-invasive diagnosis of ischaemic heart disease

Revolutionising the detection of coronary artery disease

Coronary Artery Disease (CAD) screening is largely based on exercise ECG testing that has a limited diagnostic accuracy, especially in women. Additionally, there are growing concerns over exposure to radiation and cutbacks on payment for costly cardiac imaging.

HyperQ Stress ECG testing provides a low-cost, non-invasive, radiation-free and highly reliable first line CAD diagnostic solution for private cardiology practices as well as cardiology departments in hospitals. HyperQ is based on solid scientific and clinical research.

Features

  • Higher sensitivity in diagnosing ischaemia
  • Fewer false alarms in non-ischaemic patients
  • Performs equally well in women and men
  • Provides clear results in patients with equivocal standard exercise ECG test results

Availability in your market is subject to regulatory approval.